An interventional study of Sphenopalatine block and Botulinum Toxin Type A in Sphenopalatine Block, BOTOX and Chronic Migraine, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing lidocaine in Migraine Disorders — 5 open to participants now, 5 under way, none of them phase 3. Lidocaine · Migraine Disorders.
Among the 13 studies testing lidocaine in Migraine Disorders, this one is the 5th largest by planned enrollment, is one of 3 that started in 2025, is one of 4 with no phase, and was the 10th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →5 of the 13 studies testing lidocaine in Migraine Disorders are open now, in 3 countries. Recruiting first, the newest first:
Daniel A Tonetti, MD · Sites in United States
Ages 18+
Mahidol University · Sites in Thailand
Ages 18–80
Northwell Health · Sites in United States
Ages 18–75
Assiut University
Ages 18–60
By country, each count listing its studies:
Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 64 is below the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 50 across the 13 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Cairo University has 2 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies testing lidocaine in Migraine Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06935552Assiut UniversityKetamine and Lidocaine Infusion in Refractory Chronic Migraine | 2026-11 |
| NCT07061847Northwell HealthBilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines | 2027-03-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing lidocaine in Migraine Disorders, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.
The International Headache Society's Headache Classification Committee recognizes three broad categories of headaches: primary headaches, secondary headaches, and a third catchall category called "painful cranial neuropathies, other facial pain, and other headaches." Migraines fall into the primary headache category.
Sphenopalatine ganglion (SPG), or the pterygopalatine ganglion (PPG), is a large extracranial parasympathetic ganglion with multiple neural connections, including autonomic and motor.
The botulinum toxin (BOTOX®), which can exert a paralytic effect by binding to presynaptic cholinergic nerve terminals at the neuromuscular junction, is produced by the Gram-positive, rod-shaped, spore-forming, anaerobic bacterium Clostridium botulinum. It internalizes and inhibits the exocytosis of the neurotransmitter acetylcholine by decreasing the frequency of acetylcholine release
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.
Drug: Sphenopalatine block
Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.
Drug: Botulinum Toxin Type A
Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.
Also known as: Lidocaine
Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.
Degree of pain
The patients will be shown how to use the Visual Analogue Scale (VAS); 0-10 point where 0 = no pain and 10 = worst imaginable pain. VAS will be noted as well as after procedure, four-week, and 12-weeks period.
Time frame: 12 weeks post-procedure
Percentage of patients free of headache
The percentage of patients free of headache at baseline (just before the procedure), after procedure, four-week, and 12-weeks period.
Time frame: 12 weeks post-procedure
Headache relief rate
Headache relief rate (percentage of patients with 50% or more reduction in headache intensity at four-week and 12-weeks period).
Time frame: 12 weeks post-procedure
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Oct 2025, 4 months after the start.
Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 4 months is below that.
Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lidocaine · Botulinum toxin type A